Volume Alert - SNSS 2.21 Sunesis Pharmaceuticals $SNSS Hit a high today of 2.49 Closing the day 10:30 at 2.21 -0.10 -4.33% With a day low of 2.10 and a total volume of 2,709,035.
SNSS Recent Posts: http://investorshangout.com/Sunesis-Pharmaceu...NSS-55476/
SNSS Sunesis Pharmaceuticals Recent Headline News
Sunesis Pharmaceuticals (SNSS) Jumps: Stock Surges 38.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 2 hrs 41 mins ago
Sunesis (SNSS) was a big mover last session, with shares surging over 38% on the day.
BIIB: 305.42 (+3.00), SNSS: 2.23 (-0.08), AMAG: 36.19 (+1.43), AFFX: 9.54 (+0.25)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - 2 hrs 52 mins ago
ANV: 1.87 (+0.20), AMCN: 2.44 (+0.09), UEC: 1.85 (-0.05), OME: 12.30 (-2.68), JASO: 8.20 (+0.40), ONVO: 6.88 (+0.74), SUNE: 20.65 (+4.04), NBS: 5.05 (-1.73), CYTR: 2.58 (-0.18), SNSS: 2.23 (-0.08), ETE: 64.49 (+1.78), GSAT: 2.53 (-0.27)
Market Maker Surveillance Report. SNSS, ECSL, CHOP, UGAZ, VGGL, ABGB, Winning Stocks With Lowest Price Friction For Monday, November 17th 2014
M2 - Tue Nov 18, 3:11AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 4654 companies with "abnormal" market making, 2049 companies with positive Friction Factors and 3121 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Monday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Sunesis Pharmaceuticals Inc (NASDAQ:SNSS), ECARE SOLUTIONS INC (OTC:ECSL), China Gerui Advanced Materials Group Ltd (NASDAQ:CHOP), (NYSE:UGAZ), (NASDAQ:VGGL), (:ABGB). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
VGGL: 3.55 (-0.18), UGAZ: 15.00 (-0.98), CHOP: 2.10 (-0.08), SNSS: 2.23 (-0.08)
Most active Nasdaq-traded stocks
AP - Mon Nov 17, 1:22PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
GERN: 3.10 (+0.12), FB: 74.09 (-0.15), DNDN: 0.16 (+0.01), SNSS: 2.23 (-0.08), MSFT: 49.00 (-0.46), AAPL: 114.79 (+0.80), CSCO: 26.70 (+0.23)
Sunesis Pharmaceuticals Bounces On Results Announcement
at The Street - Mon Nov 17, 12:51PM CST
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), Amicus Therapeutics, Inc. (NASDAQ:FOLD) and KiOR Inc (OTCMKTS:KIORQ) reached midday making gains this Monday. In the red today are dELiA*s, Inc. (NASDAQ
L...
DLIA: 0.10 (unch), WLH: 19.16 (+0.02), WTSL: 0.24 (unch), SNSS: 2.23 (-0.08)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:47AM CST
CADC: 5.25 (-0.35), ANV: 1.87 (+0.20), BONE: 3.10 (-0.43), WLH: 19.16 (+0.02), CLDX: 16.92 (-1.33), ENZY: 8.22 (-0.14), TGEN: 5.98 (-0.28), CHOP: 2.10 (-0.08), MSBF: 9.91 (-0.32), NVGN: 1.56 (-0.09), DWA: 22.19 (-0.12), WHX: 2.47 (-0.11), VYFC: 19.75 (unch), VGGL: 3.55 (-0.18), SNSS: 2.23 (-0.08), DNR: 9.85 (-0.16), MOBI: 6.04 (-0.34), VPCO: 1.61 (+0.08), FOLD: 6.30 (-0.40), ATEA: 1.47 (unch)
Sunesis Pharmaceuticals (SNSS) Stock Surges on Upcoming Announcement of Blood Cancer Treatment Data
at The Street - Mon Nov 17, 10:54AM CST
Shares of Sunesis Pharmaceuticals (SNSS) surged Monday after the company said it would announce results from its late-stage trial of its acute myeloid leukemia treatment in early December.
SNSS: 2.23 (-0.08)
Sunesis Pharma tries to regain some of last month's plunge
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 10:40AM CST
SNSS: 2.23 (-0.08)
Sunesis Pharmaceuticals Announces Late-Breaking Presentation of Phase 3 VALOR Trial at ASH Annual Meeting
GlobeNewswire - Mon Nov 17, 8:29AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that results from the Company's Phase 3 VALOR trial of vosaroxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia (AML) will be presented in a late-breaking oral presentation at the 56 American Society of Hematology Annual Meeting, taking place December 6-9 in San Francisco, California.
SNSS: 2.23 (-0.08)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 8:15AM CST
CADC: 5.40 (-0.20), INO: 9.92 (-0.01), CLDX: 16.92 (-1.33), HAL: 49.15 (-0.08), ROX: 1.77 (-0.06), SNSS: 2.23 (-0.08), DNR: 9.85 (-0.16), DWA: 22.19 (-0.12), GSAT: 2.53 (-0.27), CMGE: 24.64 (+0.45), FOLD: 6.30 (-0.40), BHI: 65.22 (-0.01)
Biotech Equities Technical Coverage - Orexigen Therapeutics, Novavax, Sunesis Pharma, Celldex Therapeutics, and Navidea Biopharma
PR Newswire - Mon Nov 17, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Orexigen Therapeutics Inc. (NASDAQ: OREX), Novavax Inc. (NASDAQ: NVAX), Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, November 14, 2014, the NASDAQ Composite ended at 4,688.54, up 0.18%, the Dow Jones Industrial Average edged 0.10% lower, to finish the day at 17,634.74, and the S&P 500 closed at 2,039.82, up 0.02%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 777.26, down 0.83%, while the index has advanced 9.80% in the last one month. Register for your complimentary reports on these five stocks at:
OREX: 5.59 (+0.08), NAVB: 1.21 (-0.04), NVAX: 4.96 (+0.06), CLDX: 16.92 (-1.33), SNSS: 2.23 (-0.08)
Sunesis Pharmaceuticals' (SNSS) CEO Daniel Swisher on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 2:15PM CST
SNSS: 2.23 (-0.08)
Sunesis lowers revenues 55% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 10:39AM CST
SNSS: 2.23 (-0.08)
Sunesis Pharmaceuticals (SNSS) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 10, 9:25AM CST
SNSS: 2.23 (-0.08)
Sunesis Pharmaceuticals misses by $0.08, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:14AM CST
SNSS: 2.23 (-0.08)
Sunesis Pharmaceuticals Reports Third Quarter 2014 Financial Results and Recent Highlights
GlobeNewswire - Mon Nov 10, 6:07AM CST
Announces Submission of Letter of Intent to File MAA for Vosaroxin in Relapsed or Refractory AML With the European Medicines Agency
SNSS: 2.23 (-0.08)
Notable earnings before Monday’s open
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:30PM CST
BID: 39.78 (-0.29), CRIS: 1.31 (unch), KWK: 0.61 (+0.05), ARQL: 1.24 (unch), CACQ: 10.38 (-0.04), RIG: 25.77 (-0.43), TRQ: 3.58 (+0.03), MPAA: 34.25 (-0.01), RSPP: 27.15 (-0.25), DF: 16.82 (+0.17), ENTR: 2.54 (-0.01), TA: 8.96 (-0.19), DDD: 35.76 (+0.43), RYN: 26.59 (+0.08), GAS: 51.76 (-0.47), CMCM: 19.45 (-0.05), LIOX: 5.09 (+0.12), WWAV: 37.07 (+0.54), ZINC: 16.04 (+0.03), GTXI: 0.56 (-0.03), GOGO: 16.87 (-0.13), RIGP: 18.83 (-0.16), EVEP: 29.31 (-0.26), SNSS: 2.23 (-0.08), MGIC: 7.13 (+0.06)
3 Biotech Stocks for Earnings Beats this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:38PM CST
Many biotech stocks are exploring their own ways to emerge as winners.
MDVN: 107.85 (+1.05), ENDP: 70.29 (+3.23), AUXL: 33.05 (+0.87), SHPG: 208.76 (+2.77), DNDN: 0.16 (+0.01), SNSS: 2.23 (-0.08), ABBV: 65.95 (+0.91), SNY: 48.31 (+0.77), MNKD: 6.51 (+0.25), XOMA: 4.07 (+0.09)
Sunesis to Present at Upcoming Investor Conferences
GlobeNewswire - Wed Nov 05, 6:46AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer and President of Sunesis, will present at two upcoming investor conferences:
SNSS: 2.23 (-0.08)
SNSS Recent Posts: http://investorshangout.com/Sunesis-Pharmaceu...NSS-55476/
SNSS Sunesis Pharmaceuticals Recent Headline News
Sunesis Pharmaceuticals (SNSS) Jumps: Stock Surges 38.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 2 hrs 41 mins ago
Sunesis (SNSS) was a big mover last session, with shares surging over 38% on the day.
BIIB: 305.42 (+3.00), SNSS: 2.23 (-0.08), AMAG: 36.19 (+1.43), AFFX: 9.54 (+0.25)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - 2 hrs 52 mins ago
ANV: 1.87 (+0.20), AMCN: 2.44 (+0.09), UEC: 1.85 (-0.05), OME: 12.30 (-2.68), JASO: 8.20 (+0.40), ONVO: 6.88 (+0.74), SUNE: 20.65 (+4.04), NBS: 5.05 (-1.73), CYTR: 2.58 (-0.18), SNSS: 2.23 (-0.08), ETE: 64.49 (+1.78), GSAT: 2.53 (-0.27)
Market Maker Surveillance Report. SNSS, ECSL, CHOP, UGAZ, VGGL, ABGB, Winning Stocks With Lowest Price Friction For Monday, November 17th 2014
M2 - Tue Nov 18, 3:11AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 4654 companies with "abnormal" market making, 2049 companies with positive Friction Factors and 3121 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Monday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Sunesis Pharmaceuticals Inc (NASDAQ:SNSS), ECARE SOLUTIONS INC (OTC:ECSL), China Gerui Advanced Materials Group Ltd (NASDAQ:CHOP), (NYSE:UGAZ), (NASDAQ:VGGL), (:ABGB). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
VGGL: 3.55 (-0.18), UGAZ: 15.00 (-0.98), CHOP: 2.10 (-0.08), SNSS: 2.23 (-0.08)
Most active Nasdaq-traded stocks
AP - Mon Nov 17, 1:22PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
GERN: 3.10 (+0.12), FB: 74.09 (-0.15), DNDN: 0.16 (+0.01), SNSS: 2.23 (-0.08), MSFT: 49.00 (-0.46), AAPL: 114.79 (+0.80), CSCO: 26.70 (+0.23)
Sunesis Pharmaceuticals Bounces On Results Announcement
at The Street - Mon Nov 17, 12:51PM CST
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), Amicus Therapeutics, Inc. (NASDAQ:FOLD) and KiOR Inc (OTCMKTS:KIORQ) reached midday making gains this Monday. In the red today are dELiA*s, Inc. (NASDAQ
L... DLIA: 0.10 (unch), WLH: 19.16 (+0.02), WTSL: 0.24 (unch), SNSS: 2.23 (-0.08)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:47AM CST
CADC: 5.25 (-0.35), ANV: 1.87 (+0.20), BONE: 3.10 (-0.43), WLH: 19.16 (+0.02), CLDX: 16.92 (-1.33), ENZY: 8.22 (-0.14), TGEN: 5.98 (-0.28), CHOP: 2.10 (-0.08), MSBF: 9.91 (-0.32), NVGN: 1.56 (-0.09), DWA: 22.19 (-0.12), WHX: 2.47 (-0.11), VYFC: 19.75 (unch), VGGL: 3.55 (-0.18), SNSS: 2.23 (-0.08), DNR: 9.85 (-0.16), MOBI: 6.04 (-0.34), VPCO: 1.61 (+0.08), FOLD: 6.30 (-0.40), ATEA: 1.47 (unch)
Sunesis Pharmaceuticals (SNSS) Stock Surges on Upcoming Announcement of Blood Cancer Treatment Data
at The Street - Mon Nov 17, 10:54AM CST
Shares of Sunesis Pharmaceuticals (SNSS) surged Monday after the company said it would announce results from its late-stage trial of its acute myeloid leukemia treatment in early December.
SNSS: 2.23 (-0.08)
Sunesis Pharma tries to regain some of last month's plunge
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 10:40AM CST
SNSS: 2.23 (-0.08)
Sunesis Pharmaceuticals Announces Late-Breaking Presentation of Phase 3 VALOR Trial at ASH Annual Meeting
GlobeNewswire - Mon Nov 17, 8:29AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that results from the Company's Phase 3 VALOR trial of vosaroxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia (AML) will be presented in a late-breaking oral presentation at the 56 American Society of Hematology Annual Meeting, taking place December 6-9 in San Francisco, California.
SNSS: 2.23 (-0.08)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 8:15AM CST
CADC: 5.40 (-0.20), INO: 9.92 (-0.01), CLDX: 16.92 (-1.33), HAL: 49.15 (-0.08), ROX: 1.77 (-0.06), SNSS: 2.23 (-0.08), DNR: 9.85 (-0.16), DWA: 22.19 (-0.12), GSAT: 2.53 (-0.27), CMGE: 24.64 (+0.45), FOLD: 6.30 (-0.40), BHI: 65.22 (-0.01)
Biotech Equities Technical Coverage - Orexigen Therapeutics, Novavax, Sunesis Pharma, Celldex Therapeutics, and Navidea Biopharma
PR Newswire - Mon Nov 17, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Orexigen Therapeutics Inc. (NASDAQ: OREX), Novavax Inc. (NASDAQ: NVAX), Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, November 14, 2014, the NASDAQ Composite ended at 4,688.54, up 0.18%, the Dow Jones Industrial Average edged 0.10% lower, to finish the day at 17,634.74, and the S&P 500 closed at 2,039.82, up 0.02%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 777.26, down 0.83%, while the index has advanced 9.80% in the last one month. Register for your complimentary reports on these five stocks at:
OREX: 5.59 (+0.08), NAVB: 1.21 (-0.04), NVAX: 4.96 (+0.06), CLDX: 16.92 (-1.33), SNSS: 2.23 (-0.08)
Sunesis Pharmaceuticals' (SNSS) CEO Daniel Swisher on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 2:15PM CST
SNSS: 2.23 (-0.08)
Sunesis lowers revenues 55% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 10:39AM CST
SNSS: 2.23 (-0.08)
Sunesis Pharmaceuticals (SNSS) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 10, 9:25AM CST
SNSS: 2.23 (-0.08)
Sunesis Pharmaceuticals misses by $0.08, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:14AM CST
SNSS: 2.23 (-0.08)
Sunesis Pharmaceuticals Reports Third Quarter 2014 Financial Results and Recent Highlights
GlobeNewswire - Mon Nov 10, 6:07AM CST
Announces Submission of Letter of Intent to File MAA for Vosaroxin in Relapsed or Refractory AML With the European Medicines Agency
SNSS: 2.23 (-0.08)
Notable earnings before Monday’s open
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:30PM CST
BID: 39.78 (-0.29), CRIS: 1.31 (unch), KWK: 0.61 (+0.05), ARQL: 1.24 (unch), CACQ: 10.38 (-0.04), RIG: 25.77 (-0.43), TRQ: 3.58 (+0.03), MPAA: 34.25 (-0.01), RSPP: 27.15 (-0.25), DF: 16.82 (+0.17), ENTR: 2.54 (-0.01), TA: 8.96 (-0.19), DDD: 35.76 (+0.43), RYN: 26.59 (+0.08), GAS: 51.76 (-0.47), CMCM: 19.45 (-0.05), LIOX: 5.09 (+0.12), WWAV: 37.07 (+0.54), ZINC: 16.04 (+0.03), GTXI: 0.56 (-0.03), GOGO: 16.87 (-0.13), RIGP: 18.83 (-0.16), EVEP: 29.31 (-0.26), SNSS: 2.23 (-0.08), MGIC: 7.13 (+0.06)
3 Biotech Stocks for Earnings Beats this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:38PM CST
Many biotech stocks are exploring their own ways to emerge as winners.
MDVN: 107.85 (+1.05), ENDP: 70.29 (+3.23), AUXL: 33.05 (+0.87), SHPG: 208.76 (+2.77), DNDN: 0.16 (+0.01), SNSS: 2.23 (-0.08), ABBV: 65.95 (+0.91), SNY: 48.31 (+0.77), MNKD: 6.51 (+0.25), XOMA: 4.07 (+0.09)
Sunesis to Present at Upcoming Investor Conferences
GlobeNewswire - Wed Nov 05, 6:46AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer and President of Sunesis, will present at two upcoming investor conferences:
SNSS: 2.23 (-0.08)
